· Investment Strategies · 2 sources

Canaan Partners Leads Vedana Therapeutics Series A

Canaan Partners led a Series A for Vedana Therapeutics, extending the firm’s healthcare franchise as it deploys its $850M Fund XIII.

By Venture Capital Tracker

Editorial team

Share
Canaan Partners Leads Vedana Therapeutics Series A

Canaan Partners led a Series A for Vedana Therapeutics in June 2026, extending the firm's healthcare franchise as it actively deploys its $850M Fund XIII.

Key facts

  • Lead investor: Canaan Partners
  • Company: Vedana Therapeutics (biopharma)
  • Round: Series A
  • Date: June 2026
  • Fund: Canaan XIII ($850M, April 2023); ~$6.8B total AUM
  • Track record: 73 IPOs and 152 M&As across 35+ years

Why this matters

Vedana reflects Canaan Partners' long-standing healthcare practice (Day One Biopharmaceuticals, IDEAYA, Synthekine) alongside its technology investing, all from the same multi-generation platform.

By Venture Capital Tracker

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

Related articles

See all

Frequently Asked Questions

Direct answers to common questions about this topic

Sources & references

2 sources

Reporting and documents referenced in this article.

  1. Canaan Partners portfolio (Caplight)
  2. Canaan XIII $850M announcement
Back to Blog